NO3175985T3 - - Google Patents

Info

Publication number
NO3175985T3
NO3175985T3 NO16202228A NO16202228A NO3175985T3 NO 3175985 T3 NO3175985 T3 NO 3175985T3 NO 16202228 A NO16202228 A NO 16202228A NO 16202228 A NO16202228 A NO 16202228A NO 3175985 T3 NO3175985 T3 NO 3175985T3
Authority
NO
Norway
Application number
NO16202228A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3175985T3 publication Critical patent/NO3175985T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO16202228A 2011-07-01 2012-05-31 NO3175985T3 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161503980P 2011-07-01 2011-07-01

Publications (1)

Publication Number Publication Date
NO3175985T3 true NO3175985T3 (nl) 2018-04-28

Family

ID=46513864

Family Applications (1)

Application Number Title Priority Date Filing Date
NO16202228A NO3175985T3 (nl) 2011-07-01 2012-05-31

Country Status (21)

Country Link
US (2) US8962610B2 (nl)
EP (2) EP2966067B1 (nl)
JP (3) JP6470969B2 (nl)
KR (1) KR101919634B1 (nl)
CN (2) CN107325111A (nl)
AR (1) AR086829A1 (nl)
AU (1) AU2012279214B2 (nl)
BR (1) BR112013032027A2 (nl)
CA (1) CA2838234A1 (nl)
EA (2) EA025095B1 (nl)
ES (2) ES2549654T3 (nl)
HK (2) HK1197061A1 (nl)
IL (1) IL229714B (nl)
MA (1) MA35808B1 (nl)
MX (1) MX338916B (nl)
NO (1) NO3175985T3 (nl)
PL (2) PL2726469T3 (nl)
PT (2) PT2966067T (nl)
SI (2) SI2726469T1 (nl)
TW (1) TWI466873B (nl)
WO (1) WO2013006463A1 (nl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02847B (me) * 2009-07-27 2018-01-20 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
NZ617987A (en) 2011-05-10 2016-02-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (nl) * 2011-07-01 2018-04-28
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9303043B2 (en) * 2013-03-13 2016-04-05 Greentech, Inc. Process for making benzoxazepin compounds
AR105238A1 (es) 2015-07-02 2017-09-20 Hoffmann La Roche Compuestos de benzoxacepina oxazolidinona y métodos de uso
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
CN106046021A (zh) * 2016-05-26 2016-10-26 天津药物研究院有限公司 一类含溴的噻吩并吡啶类衍生物及其制备方法和用途
US20180064726A1 (en) 2016-09-08 2018-03-08 Auspex Pharmaceuticals, Inc. Deuterium-Substituted Oxazepin Compounds
AU2017364901A1 (en) 2016-11-28 2019-06-13 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN108084187A (zh) * 2017-12-15 2018-05-29 宜昌人福药业有限责任公司 苯并二氮杂*类氢化物
US11866439B2 (en) 2018-05-30 2024-01-09 Praxis Precision Medicines, Inc. Ion channel modulators
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
TW202345852A (zh) * 2022-03-16 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠雜環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (273)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867616A (en) 1950-05-17 1959-01-06 Syntex Sa 7-dehydro diosgenin compounds and process for making same
US2867618A (en) 1957-02-14 1959-01-06 Dow Chemical Co 3, 4-dihydro-2h-1, 3-benzoxazine
US2826575A (en) 1957-05-06 1958-03-11 Dow Chemical Co 3, 3'-alkylenebis
NL128591C (nl) 1965-07-02
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
CH485411A (de) 1967-12-14 1970-02-15 Ciba Geigy Verwendung von Arylguanaminen als Antimikrobika
US3594372A (en) 1968-08-13 1971-07-20 American Home Prod Pyrimido(4,5-e)(1,4)oxazepin-5-ones and derivatives thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4062881A (en) 1974-07-26 1977-12-13 Cincinnati Milacron Chemicals, Inc. Sulfide containing tin stabilizers
US4230705A (en) 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4244953A (en) 1979-10-24 1981-01-13 American Cyanamid Company Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4812565A (en) 1982-09-30 1989-03-14 A. H. Robins Company, Incorporated Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4654343A (en) 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4746655A (en) 1987-06-10 1988-05-24 A. H. Robins Company, Incorporated Fused aromatic-spiropiperidine oxazepinones(and thiones)
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
DE4010488A1 (de) 1990-03-31 1991-10-02 Hoechst Ag Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
CN1060467A (zh) 1990-09-25 1992-04-22 武田药品工业株式会社 1，3-苯并嗪衍生物、其生产方法和用途
JPH04209692A (ja) 1990-12-03 1992-07-31 Asahi Glass Co Ltd フォトクロミック材料
EP0522606B1 (en) 1991-05-10 1996-04-03 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ES2190428T3 (es) 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
US5565449A (en) 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
US5250679A (en) 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5272158A (en) 1991-10-29 1993-12-21 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH061779A (ja) 1992-02-06 1994-01-11 Wakamoto Pharmaceut Co Ltd ベンズオキサジノン誘導体
JPH06107647A (ja) 1992-08-12 1994-04-19 Takeda Chem Ind Ltd １，３−ベンゾオキサジン誘導体の製造法
US6011150A (en) 1992-11-13 2000-01-04 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
US5442055A (en) 1992-11-13 1995-08-15 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
GB9225860D0 (en) 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9226302D0 (en) 1992-12-17 1993-02-10 Smithkline Beecham Plc Pharmaceuticals
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
DE19526173A1 (de) 1995-07-18 1997-01-30 Hoechst Ag Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung
JPH09157262A (ja) 1995-12-08 1997-06-17 Tanabe Seiyaku Co Ltd アゼチジノン誘導体及びその合成中間体の製法
US5773186A (en) 1996-02-19 1998-06-30 Fuji Photo Film Co., Ltd. Heat-sensitive recording material
AU713573B2 (en) 1996-07-26 1999-12-02 Nissan Chemical Industries Ltd. Chroman derivatives
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
GB9619492D0 (en) 1996-09-18 1996-10-30 Smithkline Beecham Plc Novel treatment
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6159979A (en) 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
DE19716237A1 (de) 1997-04-18 1998-10-22 Basf Ag Substituierte Benzyloxyimino-Verbindungen
AU7548298A (en) 1997-05-30 1998-12-30 Meiji Seika Kaisha Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
JP3964053B2 (ja) 1997-07-10 2007-08-22 三井化学株式会社 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法
EP1015544B1 (en) 1997-09-08 2001-10-24 Unilever N.V. Method for enhancing the activity of an enzyme
HUP0100575A3 (en) 1998-01-21 2003-03-28 Merck Sharp & Dohme Ltd Hoddes Triazolo-pyridazine derivatives as ligands for gaba receptors
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
AU2594799A (en) 1998-02-11 1999-08-30 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
EE200000468A (et) 1998-02-18 2002-04-15 Neurosearch A/S Ühendid, nende kasutamine ja farmatseutiline kompositsioon
CA2334258A1 (en) 1998-06-05 1999-12-09 Icagen, Inc. Potassium channel inhibitors
US6479506B1 (en) 1998-06-16 2002-11-12 Merck Sharp & Dohme Ltd. Triazolo-pyridine derivatives as ligands for GABA receptors
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6479496B1 (en) 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
CA2369103A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
CA2373073A1 (en) 1999-05-07 2000-11-16 Takeda Chemical Industries, Ltd. Cyclic compounds and uses thereof
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6121916A (en) 1999-07-16 2000-09-19 Eaton-Vorad Technologies, L.L.C. Method and apparatus for recognizing stationary objects with a moving side-looking radar
BR0013643A (pt) 1999-08-27 2002-05-07 Procter & Gamble Métodos para lavar roupa seguros para as cores empregando componentes de formulações zwitteriÈnicos
CZ2002720A3 (cs) 1999-08-27 2002-09-11 The Procter & Gamble Company Složky zesilující bělení, prostředky a způsoby praní s využitím složek zesilujících bělení
TR200201062T2 (tr) 1999-08-27 2003-02-21 The Procter & Gamble Company Formülasyon bileşenlerinin denetimli kullanılabilirliği ve bundan yararlanılan bileşimler.
MXPA02002124A (es) 1999-08-27 2002-09-18 Procter & Gamble Componentes de formulacion de incremento de estabilidad y composiciones y metodos de lavanderia que emplean los mismos.
EP1206520A1 (en) 1999-08-27 2002-05-22 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
EP1206517A1 (en) 1999-08-27 2002-05-22 The Procter & Gamble Company Color safe laundry methods employing cationic formulation components
AU7072100A (en) 1999-08-27 2001-03-26 Procter & Gamble Company, The Stable formulation components, compositions and laundry methods employing same
SK3292002A3 (en) 1999-09-17 2003-04-01 Nissan Chemical Ind Ltd Benzopyran derivative
US6555574B1 (en) 1999-09-24 2003-04-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
AU7453900A (en) 1999-10-05 2001-05-10 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
AU781365B2 (en) 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
EP1286994A1 (en) 2000-05-15 2003-03-05 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
WO2002010135A1 (fr) 2000-08-01 2002-02-07 Ono Pharmaceutical Co., Ltd. Composes derives de 3,4-dihydroisoquinoline et medicaments contenant ces composes comme principe actif
WO2002018377A1 (en) 2000-08-29 2002-03-07 Pharmacia Corporation Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
JP4854909B2 (ja) 2000-09-20 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノン系カリウムチャンネル阻害剤
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2002051441A1 (fr) 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
BR0207990A (pt) 2001-03-09 2004-04-27 Pfizer Prod Inc Compostos antinflamatórios de triazolopiridinas
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
CN1279036C (zh) 2001-06-25 2006-10-11 日产化学工业株式会社 抗心律失常的取代的苯并吡喃衍生物
JP2005089298A (ja) 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
US7122677B2 (en) 2001-11-13 2006-10-17 Scherig Corporation NK1 antagonists
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
JP2003277384A (ja) 2002-03-26 2003-10-02 Kyorin Pharmaceut Co Ltd 縮合ニ環式ピリジン誘導体
JP2003321461A (ja) 2002-04-25 2003-11-11 Kyorin Pharmaceut Co Ltd 縮合ビフェニル誘導体
BR0313724A (pt) 2002-08-13 2005-06-28 Warner Lambert Co Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US20040242572A1 (en) 2002-08-24 2004-12-02 Boehringer Ingelheim International Gmbh New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
PA8579601A1 (es) 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US7005523B2 (en) 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
AU2003262073A1 (en) 2002-09-20 2004-04-08 Tsumura And Co. Antitussives
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AU2003285946A1 (en) 2002-10-22 2004-05-13 The Trustees Of The University Of Pennsylvania Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
CN100430386C (zh) 2002-11-07 2008-11-05 默克公司 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病
PL376822A1 (pl) 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
US20060276462A1 (en) 2003-01-13 2006-12-07 Deadwyler Sam A Method of treating cognitive decline due to sleep deprivation and stress
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
DE10317526A1 (de) 2003-04-16 2004-11-04 Degussa Ag Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen
EP1622916A4 (en) 2003-04-17 2008-11-05 Merck & Co Inc Heterocyclic CYCLOPENTYLTETRAHYDROISOCHINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
JP2006524641A (ja) 2003-04-25 2006-11-02 ハー・ルンドベック・アクチエゼルスカベット 置換されたインドリンおよびインドール誘導体
WO2004101509A2 (en) 2003-05-06 2004-11-25 Case Western Reserve University Functionalized benzoxazines, polymers and copolymers thereof
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
WO2005002520A2 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2006528155A (ja) 2003-07-21 2006-12-14 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ３，７−ジアザビシクロ［３．３．１］ノナン化合物の、ヒト男性患者の抗不整脈事象治療及び／又は予防のための使用
AU2004263515A1 (en) 2003-08-05 2005-02-17 Vertex Pharmaceuticals Incorporated Condensed pyrimidine compounds as inhibitors of voltage-gated ion channels
DE10348298A1 (de) 2003-10-17 2005-05-19 Solvay Pharmaceuticals Gmbh Amidomethyl-substituierte 2-(4-Sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-ylderivade, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
TW200514582A (en) 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
BRPI0417674A (pt) 2003-12-18 2007-03-20 Pfizer Prod Inc método para tratar a inflamação aguda em animais, com inibidores de quinase map p38
JP4883296B2 (ja) 2004-03-05 2012-02-22 日産化学工業株式会社 イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
CA2568304A1 (en) 2004-06-10 2005-12-22 Xention Discovery Limited Furanopyrimidine compounds effective as potassium channel inhibitors
WO2006002470A1 (en) 2004-06-30 2006-01-12 Monash University Chiral ligands for asymmetric catalysis
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
EP1784390A2 (en) 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
WO2006023750A2 (en) 2004-08-23 2006-03-02 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
AU2005285083B2 (en) 2004-09-13 2011-03-10 Merck Sharp & Dohme Corp. Tricyclic anilide spirohydantoin CGRP receptor antagonists
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US20060094003A1 (en) 2004-11-01 2006-05-04 Stanley Nattel Acetylcholine-dependent current as a novel ionic target for atrial fibrillation
WO2006048727A1 (en) 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
JP2006203875A (ja) 2004-12-24 2006-08-03 Matsushita Electric Ind Co Ltd 受信装置
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
KR100609101B1 (ko) 2005-03-11 2006-08-08 주식회사 신화성물산 물수건 공급장치의 물 분사노즐 및 그 제조방법
CN101160301B (zh) 2005-04-12 2012-03-28 索尔瓦药物有限公司 氨基烷基-酰胺基甲基-取代的2-(4-磺酰基氨基)-3-羟基-3,4-二氢-2h-色烯-6-基衍生物以及它们作为钾通道阻断剂的用途
US7714150B2 (en) 2005-04-12 2010-05-11 Solvay Pharmaceuticals Gmbh Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives
US20080176830A1 (en) 2005-04-14 2008-07-24 Adams Nicholas D Compounds, Compositions, and Methods
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
BRPI0611948A2 (pt) 2005-06-17 2010-10-13 Wyeth Corp compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
WO2007004028A2 (en) 2005-06-30 2007-01-11 Ranbaxy Laboratories Limited Processes for the preparation of penems and its intermediate
CN101258136A (zh) * 2005-07-05 2008-09-03 阿斯利康(瑞典)有限公司 新化合物、其制备方法、中间体、药物组合物和其在治疗5－ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途
GB0516963D0 (en) 2005-08-18 2005-09-28 Carbonite Corp Liquid dispensers
WO2007023750A1 (ja) 2005-08-26 2007-03-01 National University Corporation University Of Toyama 乾燥羊膜及び羊膜の乾燥処理方法
WO2007038138A2 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
JP2009508966A (ja) 2005-09-23 2009-03-05 シェーリング コーポレイション 治療薬としての縮合四環性ｍＧｌｕＲ１アンタゴニスト
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
US8071772B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirolactam bicyclic CGRP receptor antagonists
AU2006316627A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
KR20080082618A (ko) 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
US8013073B2 (en) 2005-12-30 2011-09-06 Chevron Oronite Company Llc Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
AU2007233709A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
EP2043654A2 (en) 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thienopyrimidines useful as modulators of ion channels
EP2035372A1 (en) 2006-06-29 2009-03-18 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
US20090318412A1 (en) 2006-07-11 2009-12-24 Takahiro Matsumoto Tricyclic heterocyclic compound and use thereof
WO2008006540A1 (en) 2006-07-12 2008-01-17 Syngenta Participations Ag Triazolopyridine derivatives as herbicides
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EA016567B1 (ru) 2006-08-22 2012-05-30 Ранбакси Лабораториз Лимитед Ингибиторы матриксных металлопротеиназ
JP2010505855A (ja) 2006-10-06 2010-02-25 アボット・ラボラトリーズ 新規なイミダゾチアゾール類およびイミダゾオキサゾール類
CN101522685A (zh) * 2006-10-12 2009-09-02 泽农医药公司 三环螺-吲哚酮衍生物及其作为治疗剂的用途
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
CA2669111C (en) 2006-10-23 2016-04-12 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
BRPI0718089A2 (pt) 2006-10-28 2013-11-05 Methylgene Inc Composto, uso do composto, composição, e, métodos para inibir histona desacetilase e para tratar uma doença de expansão da poliglutamina
JPWO2008053913A1 (ja) 2006-11-02 2010-02-25 塩野義製薬株式会社 Ｍｍｐ−１３を選択的に阻害するスルホニルウレア誘導体
WO2008080012A1 (en) 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
US20100144715A1 (en) 2007-02-28 2010-06-10 Hoyt Scott B Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers
JP5497429B2 (ja) 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
CA2681444A1 (en) 2007-04-12 2008-10-23 Cv Therapeutics, Inc. Ranolazine for enhancing insulin secretion
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144483A2 (en) 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents for treating disorders involving modulation of ryanodine receptors
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090181986A1 (en) 2007-07-05 2009-07-16 Matthew Abelman Substituted heterocyclic compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US20110263569A1 (en) 2007-08-22 2011-10-27 President And Fellows Of Harvard College Ryanodine channel binders and uses thereof
KR20100054856A (ko) 2007-09-12 2010-05-25 와이어쓰 엘엘씨 히스타민-3 길항제로서의 이소퀴놀리닐 및 이소인돌리닐 유도체
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
BRPI0821394A2 (pt) 2007-12-19 2015-06-16 Wyeth Llc 4-imidazolidinonas como inibidores de canal de potássio kv1.5
BRPI0820698A2 (pt) 2007-12-19 2019-09-24 Wyeth Llc 4-imidazolidinonas como inibidores de canal de potássio kv1.5
KR20100101666A (ko) 2007-12-19 2010-09-17 제넨테크, 인크. ８-아닐리노이미다조피리딘 및 항암제 및/또는 소염제로서의 이들의 용도
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009089027A1 (en) 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
AU2009212254A1 (en) 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
KR20100124262A (ko) 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
JP2009286773A (ja) 2008-03-14 2009-12-10 Bayer Cropscience Ag 殺虫性縮環式アリール類
US20110288070A1 (en) 2008-05-05 2011-11-24 ROGERS Kathryn Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137499A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Inhibitors of histone deacetylase
DE102008024182A1 (de) 2008-05-19 2009-11-26 Merck Patent Gmbh Verbindungen für organische elektronische Vorrichtung
CA2725573A1 (en) 2008-06-06 2009-12-10 Abbott Laboratories Novel 1,2,4 oxadiazole compounds and methods of use thereof
KR101695501B1 (ko) 2008-06-17 2017-01-11 아스트라제네카 아베 피리딘 화합물
WO2010006292A1 (en) 2008-07-11 2010-01-14 Neumedics Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits
WO2010013996A1 (en) 2008-07-31 2010-02-04 Poh Huay Chua Pet carrier
MY147281A (en) 2008-07-31 2012-11-30 Invenpro M Sdn Bhd An apparatus for washing a workpiece
US8557738B2 (en) 2008-08-12 2013-10-15 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic derivative and fungicide for agricultural and horticultural use
CN102186812A (zh) 2008-08-18 2011-09-14 宇部兴产株式会社 制备氟烷基芳基亚磺酰基化合物及其氟化的化合物的方法
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
JP2012502047A (ja) 2008-09-04 2012-01-26 ギリアード サイエンシーズ， インコーポレイテッド 心房細動を治療する方法
US20100113461A1 (en) 2008-10-29 2010-05-06 Gilead Palo Alto, Inc. Substituted heterocyclic compounds
WO2010056527A2 (en) 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
US20100130436A1 (en) 2008-11-25 2010-05-27 Gilead Palo Alto, Inc. Co-administration of ranolazine and cardiac glycosides
WO2010063634A1 (en) 2008-12-05 2010-06-10 F. Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
AU2009333543A1 (en) 2008-12-08 2011-07-07 Sirtris Pharmaceuticals, Inc. Isoindolinone and related analogs as sirtuin modulators
EP2376495A4 (en) 2008-12-08 2012-10-31 Vm Pharma Llc COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
JP5271069B2 (ja) 2008-12-24 2013-08-21 三和シヤッター工業株式会社 開閉装置
FR2943342B1 (fr) 2009-03-20 2011-03-04 Servier Lab Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP5735482B2 (ja) 2009-03-27 2015-06-17 プレシディオ ファーマシューティカルズ インコーポレイテッド 縮合環のｃ型肝炎阻害剤
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
ME02847B (me) 2009-07-27 2018-01-20 Gilead Sciences Inc Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala
ES2570569T3 (es) * 2009-09-28 2016-05-19 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
WO2011042920A1 (en) 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
WO2011056985A2 (en) * 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US8323911B2 (en) 2010-05-13 2012-12-04 University Of South Carolina High throughput assay for discovering new inhibitors of the GIRK1/4 channel
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
WO2012019076A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury
WO2012019071A1 (en) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating sarcopenia
WO2012037105A1 (en) 2010-09-14 2012-03-22 The Trustees Of Columbia University In The City Of New York Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases
WO2012036233A1 (ja) 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
JP5977240B2 (ja) 2010-09-21 2016-08-24 パーデュー、ファーマ、リミテッド、パートナーシップ ブプレノルフィン類似体
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
US20140378436A9 (en) 2010-11-24 2014-12-25 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
WO2012074469A1 (en) 2010-11-30 2012-06-07 Astrazeneca Ab New ikach blockers
JP5675428B2 (ja) 2011-02-25 2015-02-25 サンドビック株式会社 ベルトプレス装置
RU2013143747A (ru) * 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
NZ617987A (en) 2011-05-10 2016-02-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
EP2714011B1 (en) 2011-06-03 2018-01-31 Signpath Pharma Inc. Liposomal mitigation of drug-induced long qt syndrome and potassium delayed-rectifier current
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
CA2840518A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
NO3175985T3 (nl) 2011-07-01 2018-04-28
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US8623860B2 (en) 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
ES2805341T3 (es) 2012-06-13 2021-02-11 Acesion Pharma Aps Composiciones farmacéuticas para terapia de combinación
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
CA2881544A1 (en) 2014-02-13 2015-08-13 Anna Chiu Solid forms of a late sodium current inhibitor
CN104844535A (zh) 2014-02-13 2015-08-19 吉利德科学公司 用于制备稠合杂环离子通道调节剂的方法

Also Published As

Publication number Publication date
TWI466873B (zh) 2015-01-01
US8962610B2 (en) 2015-02-24
AU2012279214A1 (en) 2013-05-02
JP2014518277A (ja) 2014-07-28
SI2966067T1 (en) 2018-02-28
CN107325111A (zh) 2017-11-07
CN103635467A (zh) 2014-03-12
BR112013032027A2 (pt) 2016-09-06
KR101919634B1 (ko) 2018-11-16
TW201313692A (zh) 2013-04-01
US9695192B2 (en) 2017-07-04
US20130005706A1 (en) 2013-01-03
EP2726469A1 (en) 2014-05-07
EP2726469B1 (en) 2015-08-12
PT2966067T (pt) 2018-01-30
CN103635467B (zh) 2017-08-04
ES2657169T3 (es) 2018-03-01
PL2726469T3 (pl) 2016-01-29
SI2726469T1 (sl) 2015-10-30
EP2966067A1 (en) 2016-01-13
ES2549654T3 (es) 2015-10-30
HK1219098A1 (zh) 2017-03-24
MX2013014843A (es) 2014-03-31
NZ618684A (en) 2016-02-26
PT2726469E (pt) 2015-10-27
AR086829A1 (es) 2014-01-22
JP6470969B2 (ja) 2019-02-13
CA2838234A1 (en) 2013-01-10
EA201391628A1 (ru) 2014-06-30
AU2012279214B2 (en) 2015-07-30
JP2017088630A (ja) 2017-05-25
EA201690899A1 (ru) 2016-12-30
PL2966067T3 (pl) 2018-04-30
EA025095B1 (ru) 2016-11-30
IL229714A0 (en) 2014-01-30
MA35808B1 (fr) 2014-12-01
EP2966067B1 (en) 2017-10-25
EA031189B1 (ru) 2018-11-30
WO2013006463A1 (en) 2013-01-10
MX338916B (es) 2016-05-03
KR20140045394A (ko) 2014-04-16
IL229714B (en) 2018-04-30
HK1197061A1 (en) 2015-01-02
US20150239904A1 (en) 2015-08-27
JP2018203771A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
BR112013022641A2 (nl)
AP3853A (nl)
BR112013024383A2 (nl)
BR112013023185A2 (nl)
BR112013022995A2 (nl)
BR112013023927A2 (nl)
BR112013024365A2 (nl)
AP2016009466A0 (nl)
NO3175985T3 (nl)
BR112013032380A2 (nl)
BR112013032377A2 (nl)
BR112013018949A2 (nl)
BR112013021637A2 (nl)
BR112013023266A2 (nl)
BR112013032392A2 (nl)
BR112013017878A2 (nl)
BR112013032394A2 (nl)
BR112013022499A2 (nl)
AP3777A (nl)
BR112013019418A2 (nl)
AP3936A (nl)
CN301884589S (zh) 上衣（28）
AU2011354598A1 (nl)
CN301585191S (zh) 布（1100265）
CN301585169S (zh) 布（1100243）